Company Overview and News

 
Tan’s Alliance Global earmarks P240B for projects until 2020

2018-09-18 bworldonline
ALLIANCE Global Group, Inc. (AGI) is ramping up its investments to P240 billion until 2020, pushing the expansion of its property, liquor, gaming, and quick- serviced restaurant businesses in the next three years.
RWM ALGGY ALGGF AGI

 
Infracorp plans monorail project linking Eastwood City to MRT-3

2018-09-18 bworldonline
INFRACORP Development, Inc. looks to propose a monorail project connecting the Metro Rail Transit Line 3 (MRT-3) to Eastwood City, in a bid to ease traffic congestion and increase connectivity for commuters in the area.
FILIY JGSMY ALGGY JGS MPCFF MPCIY MPI ALGGF FDC AGI JGSHF

 
AGI sets P240-B capex up to 2020

2018-09-18 bworldonline
LISTED investment holding firm Alliance Global Group, Inc. (AGI) said it will be allocating P240 billion in capital expenditures (capex) to be spent over three years until 2020.
ALGGY ALGGF AGI

 
NAIA consortium’s P102-B proposal gains ground

2018-09-13 bworldonline
A CONSORTIUM composed of seven of the country’s biggest conglomerates has been given original proponent status (OPS) by the government for its P102-billion proposal to rehabilitate and expand the Ninoy Aquino International Airport (NAIA).
JGSMY JGS MPCIY GMQRY GMRINFRA 532754 FILIY ALGGY MWP MPI MPCFF ALGGF FDC AGI MWIDE JGSHF

 
Villar breaks into Sy-led 10 richest Filipinos list

2018-09-06 bworldonline
HENRY SY, Sr. remains the country’s wealthiest man for the 11th straight year in Forbes Asia’s “Philippines’ 50 Richest” list, which reflected the economy’s overall volatility as many registered shifts in wealth from 2017.
ICT JGSMY GTCAP GTCXY SVTMF NIKL SMCP1 JGS SM ICTEF SECB SMGBF SMIVY SMC ALGGY SBS AGI JGSHF GMA7 SMGBY NIKAY SMC2B SMC2A SMC2D TECH SMC2C SMC2F SYBJF SMC2E ALGGF GNWKY LTG

 
Group says no subsidy in Naia rehab offer

2018-09-05 business.inquirer.net
A consortium formed by seven of the country’s biggest conglomerates insisted on Wednesday that it was not seeking any government guarantees, the existence of which could jeopardize its offer to modernize and operate Manila’s Ninoy Aquino International Airport (Naia) for 15 years.
JGSMY JGS MPCIY AEV FILIY ALGGY ABTZY MPI MPCFF ALGGF FDC AGI JGSHF

 
NAIA consortium says proposed terminal fee hike is not a ‘gov’t guarantee’

2018-09-05 bworldonline
THE CONSORTIUM proposing to rehabilitate the Ninoy Aquino International Airport (NAIA) on Wednesday said it is not seeking any government guarantees in its bid to develop and expand the gateway.
FILIY JGSMY ALGGY JGS MPCFF MPCIY MPI ALGGF FDC AGI JGSHF

 
More airport dev’t needed after NAIA closure

2018-08-21 bworldonline
THE Department of Transportation (DoTr) said the disruption to air travel caused by the airport closure caused by the botched landing of a XiamenAir jet last week highlights the need to develop alternative gateways and upgrade systems at existing airports.
JGSMY SMCP1 JGS GMRINFRA GMQRY 532754 SMGBF SMC ALGGY MWP MPCFF MWIDE AGI JGSHF MPCIY SMGBY FILIY SMC2B SMC2A SMC2D SMC2C MPI SMC2F SMC2E ALGGF FDC

 
DoTr chief outlines airport roadmap

2018-08-17 bworldonline
TRANSPORTATION Secretary Arthur P. Tugade outlined the government’s airport roadmap to include multiple airports connecting Bulacan, Cavite, and NCR.
FILIY JGSMY ALGGY JGS MPCFF MPCIY MPI ALGGF FDC AGI JGSHF

 
Alliance Global H1 net up 17% to P7.9B

2018-08-11 business.inquirer.net
Tycoon Andrew Tan-led conglomerate Alliance Global Group Inc. (AGI) grew its net profit in the first semester by 17 percent year-on-year to P7.9 billion on higher earnings across its real estate, gaming, liquor and food retailing businesses.
ALGGY ALGGF AGI

 
Bourse wobbles in wake of economic data, hawkish policy action

2018-08-11 bworldonline
THE BOURSE continued to reel from worrisome economic data that peppered this week, seesawing between muted gains and losses for much of Friday but ending relatively flat and capping recent week-on-week increases.
SMCP1 RBLAY SECB SMGBF SMC ALGGY PHSXY PSE SPHXF AGI SPHZF PSKXF SMGBY SMPH SMC2B SMC2A SMC2D RLC SMC2C SMC2F SPHXY SYBJF SMC2E ALGGF BBRRF BLOOM

 
Alliance Global’s first-half profit rises 17%

2018-08-10 bworldonline
Alliance Global Group, Inc. grew its attributable profit by 17% in the first half of 2018, driven by the double-digit growth across its property, liquor, and fast food businesses, alongside the recovery in its gaming unit.
ALGGY ALGGF AGI

 
Rental revenues boost GERI’s first-half profit

2018-08-07 bworldonline
GLOBAL-ESTATE Resorts, Inc. (GERI) posted an 18% attributable profit growth during the first six months of 2018, driven by a surge in rental revenues after it opened its first full-scale mall in Laguna.
ALGGY GERI ALGGF AGI

 
Cavite government’s Sangley airport plan gets green light from Transportation dep’t

2018-07-29 bworldonline
THE DEPARTMENT of Transportation (DoTr) has given the green light to the Cavite provincial government’s plan to build an airport at the former US naval facility at Sangley Point, Cavite.
JGSMY SMCP1 JGS MPCIY SMGBY SMGBF FILIY SMC2B SMC2A SMC SMC2D ALGGY SMC2C MPI MPCFF SMC2F SMC2E ALGGF FDC AGI JGSHF

1
Naia Consortium proposal gets DOTr nod

2018-07-17 business.inquirer.net - 1
A proposal by seven local conglomerates to upgrade and operate Manila’s Manila’s Ninoy Aquino International Airport, the country’s busiest air gateway, is set to move forward.
JGSMY JGS MPCIY AEV FILIY ALGGY ABTZY MPI MPCFF ALGGF FDC AGI JGSHF

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...